<?xml version="1.0" encoding="UTF-8"?>
<p id="Par95">The University of Hong Kong is working on a live influenza vaccine that expresses SARS-CoV-2 proteins. It is a Modified nasal spray influenza vaccine, with the surface antigen of SARS-CoV-2 and can prevent both influenza and coronavirus. This one is also at a preclinical stage, and it should be tested on animals for months and after that, it should endure at least 1 year of clinical trials on humans [
 <xref ref-type="bibr" rid="CR110">110</xref>].
</p>
